ILMN vs TMO vs RGEN Stock Comparison

Illumina, Thermo Fisher Scientific and Repligen Prices as of Nov 13, 2026 Peers: Industry group
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$30.31B
P/E
33.9x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.33B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Illumina leads on 5 of the 12 questions below (Illumina 5, Thermo Fisher Scientific 4, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionILMNTMORGENLeader
Larger companyMarket capitalisation $30.31B $257.03B $9.33B TMO
Cheaper on earningsLower P/E, profitable companies only 33.9x 36.3x -790.3x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 40.9x 27.0x 86.0x TMO
Faster revenue growthRevenue growth, trailing twelve months +5.8% +8.3% +13.8% RGEN
More profitableNet margin, trailing twelve months 19.7% 14.9% -1.5% ILMN
Better return on capitalReturn on invested capital 16.6% 8.0% 0.0% ILMN
Less leveragedLower net debt / EBITDA 0.4x 3.1x -2.8x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +72.6% +20.7% +11.4% ILMN
Better 5-year returnAnnualised price return, 5 years -11.1%/yr +2.0%/yr -8.3%/yr TMO
Less volatileAnnualised volatility, 1 year 51.1% 30.7% 46.5% TMO
Higher overall scoreMean of the five percentile scores vs peers 75/100 60/100 58/100 ILMN

Percentile Scorecard

ILMNTMORGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisILMNTMORGEN
Valuation 63 #91 of 243 62 #94 of 243 56 #108 of 243
Growth 73 #63 of 228 41 #136 of 228 30 #161 of 228
Profitability 98 #5 of 222 82 #40 of 222 67 #75 of 222
Financial Health 57 #107 of 248 31 #172 of 248 80 #50 of 248
Shareholder Returns 85 #25 of 158 82 #29 of 158 57 #68 of 158
Overall 75 60 58
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodILMNTMORGENSPY
1 month -23.8%+4.0%-5.8% -2.0%
3 months +8.4%+19.1%+0.6% -2.8%
6 months +45.2%+59.7%+63.1% +2.0%
Year to date +57.8%+20.8%+2.4% +10.6%
1 year +72.6%+20.7%+11.4% +12.2%
3 years +118.3%+52.5%+9.1% +68.1%
3 years, per year +29.7%+15.1%+2.9% +18.9%
5 years -44.5%+10.2%-35.1% +61.4%
5 years, per year -11.1%+2.0%-8.3% +10.1%
10 years +54.5%+362.9%+419.6% +248.5%
10 years, per year +4.4%+16.6%+17.9% +13.3%

Risk

MeasureILMNTMORGENSPY
Volatility, 1Y 51.1%30.7%46.5% 13.6%
Downside volatility, 1Y 50.9%29.2%47.4% 13.9%
Beta vs S&P 500, 1Y 1.110.711.21 1.00
Return / volatility, 1Y 1.420.670.25 0.90
Max drawdown, 5Y -82.9%-41.5%-64.7% -25.4%
From 52-week high -29.5%-3.0%-13.8% -3.2%
52-week high $293.69$721.63$194.57 $779.14
52-week low $114.44$438.34$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleILMNTMORGEN
P/E now vs peer median 34.9xmedian 26.5x 36.6xmedian 26.5x -804.0xmedian 26.5x
P/S now vs peer median 6.9xmedian 2.7x 5.5xmedian 2.7x 11.8xmedian 2.7x
EV/EBITDA now vs peer median 25.7xmedian 18.4x 25.5xmedian 18.4x 83.9xmedian 18.4x
P/FCF now vs peer median 29.6xmedian 25.4x 34.2xmedian 25.4x 89.1xmedian 25.4x
P/B now vs peer median 10.0xmedian 2.5x 4.7xmedian 2.5x 4.5xmedian 2.5x
PEG now vs peer median 0.85median 0.98 4.84median 0.98 28.28median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsILMNTMORGEN
Revenue $4.54B $47.35B $805.61M
Gross profit $3.08B $19.45B $430.67M
Operating income $960.00M $8.47B $18.24M
Net income $895.00M $7.09B -$11.80M
Free cash flow $1.06B $7.60B $106.72M
R&D $975.00M $1.40B $57.23M
EPS (diluted) $5.81 $19.06 $-0.21
Cash & equivalents $1.29B $5.46B $726.96M
Total debt $1.79B $41.37B $555.60M
Shares (diluted) 154.00M 371.00M 56.56M
Enterprise value $25.02B $233.55B $6.10B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricILMNTMORGEN
P/E 34.9x 36.6x -804.0x
P/FCF 29.6x 34.2x 89.1x
P/Operating cash flow 25.4x 27.8x 73.2x
P/S 6.9x 5.5x 11.8x
P/B 10.0x 4.7x 4.5x
P/Tangible book 11.4x 7.1x 5.3x
EV/EBITDA 25.7x 25.5x 83.9x
EV/EBIT 33.1x 34.8x 504.7x
EV/Revenue 7.0x 6.2x 11.4x
EV/FCF 30.0x 38.8x 86.3x
EV/Operating cash flow 25.8x 31.6x 70.9x
PEG (3Y EPS CAGR) 0.85 4.84 28.28

Growth

14 metrics
MetricILMNTMORGEN
Revenue growth (1Y) 5.8% 8.3% 13.8%
Revenue CAGR (3Y) -0.7% 2.9% 7.3%
Gross profit growth (1Y) 8.5% 7.8% 33.0%
Gross profit CAGR (3Y) 4.4% 4.0% 13.3%
Operating income growth (1Y) 23.1% 12.8% 2,185%
Operating income CAGR (3Y) 30.0% 7.2% -40.5%
Net income growth (1Y) 27.5% 7.9% -779.2%
Net income CAGR (3Y) 40.9% 6.2% -28.4%
EPS growth (1Y) 27.5% 9.7% -778.9%
EPS CAGR (3Y) 41.2% 7.6% -28.4%
Operating cash flow growth (1Y) 9.6% 21.9% -0.8%
Operating cash flow CAGR (3Y) 47.5% 4.5% 5.3%
Free cash flow growth (1Y) 5.7% 24.3% -3.0%
Free cash flow CAGR (3Y) 126.5% 5.1% 17.6%

Profitability

14 metrics
MetricILMNTMORGEN
Gross margin 67.9% 41.1% 53.5%
EBITDA margin 27.3% 24.4% 13.6%
Operating margin 21.2% 17.9% 2.3%
Pretax margin 23.3% 16.7% 1.0%
Net margin 19.7% 14.9% -1.5%
FCF margin 23.3% 16.0% 13.2%
Operating cash flow margin 27.1% 19.7% 16.1%
Return on equity 29.9% 13.2% -1.7%
Return on assets 13.3% 6.2% -1.2%
Return on invested capital 16.6% 8.0% 0.0%
Return on capital employed 17.2% 8.5% 0.6%
Asset turnover 0.7x 0.4x 0.3x
Cash conversion (OCF / net income) 1.4x 1.3x -11.0x
Stock comp / revenue 5.9% 0.7% 4.2%

Financial Health

11 metrics
MetricILMNTMORGEN
Debt / assets 26.3% 36.2% 19.0%
Debt / equity 0.6x 0.8x 0.3x
Net debt / EBITDA 0.4x 3.1x -2.8x
Debt / FCF 1.7x 5.4x 5.2x
Liabilities / assets 53.8% 52.1% 28.5%
Equity / assets 46.2% 47.9% 71.5%
Interest coverage 9.8x 12.0x 0.8x
Current ratio 2.6x 1.8x 9.9x
Quick ratio 1.8x 1.2x 8.1x
Cash ratio 1.2x 0.4x 6.9x
Altman Z-score 6.62 4.18 7.80

Shareholder Returns

7 metrics
MetricILMNTMORGEN
Dividend yield – 0.3% –
Net buyback yield 1.2% 1.6% -0.2%
Shareholder yield 1.2% 1.8% -0.2%
Payout ratio (earnings) – 9.5% –
Payout ratio (FCF) – 8.9% –
Dividend growth (1Y) – 8.0% –
Dividend CAGR (3Y) – 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusILMNTMORGEN
Forward P/E 40.9xFY2026 27.0xFY2026 86.0xFY2026
EPS, next fiscal year $5.06FY2026 $25.92FY2026 $1.95FY2026
EPS growth, next FY +4.5%FY2026 +13.3%FY2026 +14.0%FY2026
EPS growth, the year after +25.1% +2.2% +29.2%
Revenue, next fiscal year $4.53BFY2026 $50.12BFY2026 $791.31MFY2026
Revenue growth, next FY +4.4%FY2026 +12.5%FY2026 +7.2%FY2026
Revenue growth, the year after +12.6% -2.7% +44.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersILMNTMORGEN
Held by institutions 100.0% 90.2% 100.0%
Institutions holding 935 2,627 483
Change in shares held, QoQ +0.0% +0.8% +1.2%
Institutions buying 464 1,145 273
Institutions selling 331 1,145 141
Buyers to sellers 1.40 1.00 1.94

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ILMNTMORGEN
ILMN 1.00 0.53 0.48
TMO 0.53 1.00 0.68
RGEN 0.48 0.68 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ILMN, TMO and RGEN?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Illumina (ILMN) $30.31B, Thermo Fisher Scientific (TMO) $257.03B, Repligen (RGEN) $9.33B.

Which stock is cheaper, ILMN, TMO and RGEN?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Illumina (ILMN) 33.9x, Thermo Fisher Scientific (TMO) 36.3x, Repligen (RGEN) -790.3x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Illumina (ILMN) 40.9x, Thermo Fisher Scientific (TMO) 27.0x, Repligen (RGEN) 86.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Illumina (ILMN) +5.8%, Thermo Fisher Scientific (TMO) +8.3%, Repligen (RGEN) +13.8%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Illumina (ILMN) 19.7%, Thermo Fisher Scientific (TMO) 14.9%, Repligen (RGEN) -1.5%). On return on invested capital, Illumina (ILMN) leads (Illumina (ILMN) 16.6%, Thermo Fisher Scientific (TMO) 8.0%, Repligen (RGEN) 0.0%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Illumina (ILMN) +72.6%, Thermo Fisher Scientific (TMO) +20.7%, Repligen (RGEN) +11.4%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Illumina (ILMN) -11.1%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Repligen (RGEN) -8.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Illumina (ILMN) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Repligen (RGEN) 0.00%. Illumina (ILMN) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Illumina (ILMN) 51.1%, Thermo Fisher Scientific (TMO) 30.7%, Repligen (RGEN) 46.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ILMN, TMO and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.